基于群体药动学的利奈唑胺个体化给药研究进展

邱红玉; 荣礼; 谢梦圆; 孔令提

doi:10.6039/j.issn.1001-0408.2023.05.23

您当前的位置：

首页 >

文章列表页 >

基于群体药动学的利奈唑胺个体化给药研究进展

综述 | 更新时间：2023-06-12

- 基于群体药动学的利奈唑胺个体化给药研究进展
- Research progress on individualized administration of linezolid based on population pharmacokinetics
- 中国药房 2023年34卷第5期页码：636-640
- 作者机构：
  
  1.蚌埠医学院第一附属医院药剂科，安徽蚌埠　233004
  2.蚌埠医学院药学院，安徽蚌埠　233030
- 作者简介：
  
  硕士研究生。研究方向：临床药学。E-mail：Qiuhongyu321@163.com
  副主任药师，硕士生导师，博士。研究方向：临床药学。E-mail：konglingti@163.com
- 基金信息：
  
  蚌埠医学院“512人才培育计划”项目(by51201316)
- DOI：10.6039/j.issn.1001-0408.2023.05.23
  中图分类号： R969.1
- 纸质出版日期：2023-03-15，
  
  收稿日期：2022-06-29，
  
  修回日期：2023-01-03，
扫描看全文
邱红玉,荣礼,谢梦圆等.基于群体药动学的利奈唑胺个体化给药研究进展 ^Δ[J].中国药房,2023,34(05):636-640.

QIU Hongyu,RONG Li,XIE Mengyuan,et al.Research progress on individualized administration of linezolid based on population pharmacokinetics[J].ZHONGGUO YAOFANG,2023,34(05):636-640.
邱红玉,荣礼,谢梦圆等.基于群体药动学的利奈唑胺个体化给药研究进展 ^Δ[J].中国药房,2023,34(05):636-640. DOI： 10.6039/j.issn.1001-0408.2023.05.23.

QIU Hongyu,RONG Li,XIE Mengyuan,et al.Research progress on individualized administration of linezolid based on population pharmacokinetics[J].ZHONGGUO YAOFANG,2023,34(05):636-640. DOI： 10.6039/j.issn.1001-0408.2023.05.23.

摘要

利奈唑胺是一种治疗多重耐药革兰氏阳性菌感染的抗菌药物，目前在临床广泛使用。但其在患者体内的药动学特征存在较大的个体差异，按说明书常规剂量给药较难获得最佳疗效。因此，有必要对利奈唑胺进行治疗药物监测（TDM），并利用群体药动学（PPK）和药效学原理指导和优化其抗菌治疗方案。本文总结了利奈唑胺在各种人群中的PPK变化及个体化给药研究进展，建议临床使用利奈唑胺时，应通过TDM将患者稳态血药浓度保持在2～8 mg/mL；对于肝肾功能不全的患者，应适当降低利奈唑胺给药剂量，而对于肥胖、烧伤、儿童患者应适当增加利奈唑胺给药剂量，并在用药过程中提供药学监护，以促进合理用药。

Abstract

Linezolid is an antibacterial agent for the treatment of multi-resistant Gram-positive bacterial infections， which is widely used in clinical practice. However， there are large individual differences in the pharmacokinetic characteristics of the drug in patients， and it is difficult to obtain the optimal therapeutic effect when the drug is administered according to the conventional dose in the instructions. Therefore， it is necessary to carry out therapeutic drug monitoring （TDM） for linezolid， and guide and optimize its antibacterial treatment plan by using population pharmacokinetics （PPK） and pharmacodynamics principles. This paper summarizes the PPK changes and the research progress of individualized administration of linezolid in various populations， and recommends that the patient’s steady-state blood concentration is kept at 2-8 mg/mL through TDM when using linezolid clinically. It is recommended to appropriately reduce the dosage for patients with liver and kidney dysfunction， appropriately increase the dosage for obese， burned and children patients， and provide pharmaceutical monitoring during the medication process to promote rational drug use.

关键词

利奈唑胺群体药动学抗菌个体化给药

Keywords

population pharmacokineticsantibacterialindividualized administration

references

SADEGHI MOGHADDAM T，NAMAEI M H，AFSHAR D，et al. High frequency of SCCmec type Ⅳ and multidrug-resistant SCCmec type Ⅰ among hospital acquired methicillin-resistant Staphylococcus aureus isolates in Birjand Imam Reza Hospital，Iran[J]. Iran J Microbiol，2022，14（1）：67-75.

唐翎，刘春军. 利奈唑胺临床应用研究概述[J]. 中国药师，2012，15（9）：1345-1347.

TAYAL A，SINGH N P，RAI S，et al. First study on detection of cryptic resistance to linezolid among clinical isolates of methicillin resistant Staphylococcus aureus from India[J]. Indian J Med Microbiol，2022，40（3）：384-388.

YANG G，YAN Y S，MAO J，et al. Development and validation of an HPLC-UV method for quantitation of linezolid：application to resistance study using in vitro PK/PD model[J]. Infect Drug Resist，2021，14：5089-5098.

MOCKELIUNAS L，KEUTZER L，STURKENBOOM M G G，et al. Model-informed precision dosing of linezolid in patients with drug-resistant tuberculosis[J]. Pharmaceutics，2022，14（4）：753.

BO S Y，SU A M，YANG F，et al. Risk factors for development of hematotoxicity in elderly patients treated with linezolid[J]. Zhonghua Jie He He Hu Xi Za Zhi，2022，45（6）：533-538.

KAWASUJI H，TSUJI Y，OGAMI C，et al. Initially reduced linezolid dosing regimen to prevent thrombocytopenia in hemodialysis patients[J]. Antibiotics （Basel），2021，10（5）：496.

SAZDANOVIC P，JANKOVIC S M，KOSTIC M，et al. Pharmacokinetics of linezolid in critically ill patients[J]. Expert Opin Drug Metab Toxicol，2016，12（6）：595-600.

ONG V，FLANAGAN S，FANG E，et al. Absorption，distribution，metabolism，and excretion of the novel antibacterial prodrug tedizolid phosphate[J]. Drug Metab Dispos，2014，42（8）：1275-1284.

EL-GAML R M，EL-KHODARY N M，ABOZAHRA R R，et al. Applying pharmacokinetic/pharmacodynamic measurements for linezolid in critically ill patients：optimizing efficacy and reducing resistance occurrence[J]. Eur J Clin Pharmacol，2022，78（8）：1301-1310.

HEIDARI S，KHALILI H. Linezolid pharmacokinetics：a systematic review for the best clinical practice[J]. Eur J Clin Pharmacol，2023，79（2）：195-206.

SLATTER J G，STALKER D J，FEENSTRA K L，et al. Pharmacokinetics，metabolism，and excretion of linezolid following an oral dose of [（14）C]linezolid to healthy human subjects[J]. Drug Metab Dispos，2001，29（8）：1136-1145.

MEAGHER A K，FORREST A，RAYNER C R，et al. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program[J]. Antimicrob Agents Chemother，2003，47（2）：548-553.

ZHOU W Q，NIE W J，WANG Q F，et al. Linezolid pharmacokinetics/pharmacodynamics-based optimal dosing for multidrug-resistant tuberculosis[J]. Int J Antimicrob Agents，2022，59（6）：106589.

WANG X P，WANG Y F，YAO F，et al. Pharmacokinetics of linezolid dose adjustment for creatinine clearance in critically ill patients：a multicenter，prospective，open-label，observational study[J]. Drug Des Devel Ther，2021，15：2129-2141.

RAYNER C R，FORREST A，MEAGHER A K，et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme[J]. Clin Pharmacokinet，2003，42（15）：1411-1423.

ZHENG X B，DAVIES FORSMAN L，BAO Z W，et al. Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis：a multicentre prospective cohort study in China[J]. Eur Respir J，2022，59（3）：2101925.

MAO J，LI T，ZHANG N，et al. Dose optimization of combined linezolid and fosfomycin against Enterococcus by using an in vitro pharmacokinetic/pharmacodynamic model[J]. Microbiol Spectr，2021，9（3）：e0087121.

VINH D C，RUBINSTEIN E. Linezolid：a review of safety and tolerability[J]. J Infect，2009，59（Suppl 1）：S59-S74.

TSUJI Y，HIRAKI Y，MATSUMOTO K，et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction[J]. J Infect Chemother，2011，17（1）：70-75.

DAI Y，JIANG S Y，CHEN X O，et al. Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients[J]. J Clin Pharm Ther，2021，46（3）：807-813.

CATTANEO D，GERVASONI C，COZZI V，et al. Therapeutic drug management of linezolid：a missed opportunity for clinicians?[J]. Int J Antimicrob Agents，2016，48（6）：728-731.

LIU C，BAYER A，COSGROVE S E，et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children：executive summary[J]. Clin Infect Dis，2011，52（3）：285-292.

DAVID N. GILBERT M D.热病：桑福德抗微生物治疗指南[M]. 48版.北京：中国协和医科大学出版社，2019：96-109.

ZAHEDI BIALVAEI A，RAHBAR M，YOUSEFI M，et al. Linezolid：a promising option in the treatment of gram-positives[J]. J Antimicrob Chemother，2017，72（2）：354-364.

WU F，ZHANG X S，DAI Y，et al. Dosage strategy of linezolid according to the trough concentration target and renal function in Chinese critically ill patients[J]. Front Pharmacol，2022，13：844567.

BANDÍN-VILAR E，GARCÍA-QUINTANILLA L，CASTRO-BALADO A，et al. A review of population pharmacokinetic analyses of linezolid[J]. Clin Pharmacokinet，2022，61（6）：789-817.

PEA F，VIALE P，COJUTTI P，et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients[J]. J Antimicrob Chemother，2012，67（8）：2034-2042.

ZOLLER M，MAIER B，HORNUSS C，et al. Variability of linezolid concentrations after standard dosing in critically ill patients：a prospective observational study[J]. Crit Care，2014，18（4）：R148.

曹伟，卢志品，余剑华. 利奈唑胺是否需要血药浓度监测[J]. 中国新药与临床杂志，2016，35（10）：690-694.

RAO G G，KONICKI R，CATTANEO D，et al. Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice：a review of linezolid pharmacokinetics and pharmacodynamics[J]. Ther Drug Monit，2020，42（1）：83-92.

LI L，LI X，XIA Y Z，et al. Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy[J]. Front Pharmacol，2020，11：786.

KÜHN D，METZ C，SEILER F，et al. Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygena- tion （ECMO） and renal replacement therapy：a prospective，observational single-center study[J]. Crit Care，2020，24（1）：664.

FAYAD A I，BUAMSCHA D G，CIAPPONI A. Timing of kidney replacement therapy initiation for acute kidney injury[J]. Cochrane Database Syst Rev，2022，11（11）：CD010612.

BARRASA H，SORALUCE A，ISLA A，et al. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy：influence of residual renal function on PK/PD target attainment[J]. J Crit Care，2019，50：69-76.

CORCIONE S，D’AVOLIO A，ALLEGRA S，et al. Pharmacokinetics of linezolid in critically ill patients：impact of continuous venovenous haemofiltration[J]. Int J Antimicrob Agents，2017，49（6）：784-785.

IDE T，TAKESUE Y，IKAWA K，et al. Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy[J]. Int J Antimicrob Agents，2018，51（5）：745-751.

WICHA S G，MAIR A，CHIRIAC U，et al. Population pharmacokinetics and toxicodynamics of continuously infused linezolid in critically ill patients[J]. Int J Antimicrob Agents，2022，59（5）：106572.

LE FLOCH R，ARNOULD J F，VINSONNEAU C，et al. Pharmacocinétique du linézolide chez des patients souffrant de brûlures sévères[J]. Pathol Biol，2010，58（2）：e27-e31.

TSUJI Y，YUKAWA E，HIRAKI Y，et al. Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction[J]. J Clin Pharmacol，2013，53（9）：967-973.

FIACCADORI E，MAGGIORE U，ROTELLI C，et al. Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation[J]. Nephrol Dial Transplant，2006，21（5）：1402-1406.

CHENG C N，LIN S W，WU C C. Early linezolid-associated lactic acidosis in a patient with Child’s class C liver cirrhosis and end stage renal disease[J]. J Infect Chemother，2018，24（10）：841-844.

ZHANG S H，ZHU Z Y，CHEN Z，et al. Population pharmacokinetics and dosage optimization of linezolid in patients with liver dysfunction[J]. Antimicrob Agents Chemother，2020，64（6）：e00133-e00120.

XIE F F，MANTZARLIS K，MALLIOTAKIS P，et al. Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia[J]. J Antimicrob Chemother，2019，74（3）：667-674.

张雷，白楠，刘又宁，等. 利奈唑胺在中国人的群体药代动力学特点[J]. 中华结核和呼吸杂志，2016，39（12）：924-928.

MIYAMOTO T，TOMOYASU T，MIYAJI K. Successful treatment of pediatric endocarditis and pericarditis due to MRSA with linezolid[J]. Jpn J Antibiot，2011，64（2）：109-112.

李思婵，徐华，叶琦，等. 利奈唑胺成人药动学数据在儿童群体中的外推及暴露量-疗效关系研究[J]. 中国医院药学杂志，2019，39（7）：720-726.

LI S C，YE Q，XU H，et al. Population pharmacokinetics and dosing optimization of linezolid in pediatric patients[J]. Antimicrob Agents Chemother，2019，63（4）：e02387-e02318.

JELLIFFE R W. Some comments and suggestions concerning population pharmacokinetic modeling，especially of digoxin，and its relation to clinical therapy[J]. Ther Drug Monit，2012，34（4）：368-377.

张弨，翟所迪. 群体药动学在治疗药物监测中的应用[J]. 临床药物治疗杂志，2006，4（1）：45-50.

SANTIMALEEWORAGUN W，CHANGPRADUB D，HEMAPANPAIROA J，et al. Optimization of linezolid dosing regimens for treatment of vancomycin-resistant enterococci infection[J]. Infect Chemother，2021，53（3）：503-511.

BLACKMAN A L，JARUGULA P，NICOLAU D P，et al. Evaluation of linezolid pharmacokinetics in critically ill obese patients with severe skin and soft tissue infections[J]. Antimicrob Agents Chemother，2021，65（2）：e01619-e01620.

ALGHAMDI W A，AL-SHAER M H，AN G H，et al. Population pharmacokinetics of linezolid in tuberculosis patients：dosing regimen simulation and target attainment analysis[J]. Antimicrob Agents Chemother，2020，64（10）：e01174-e01120.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

吡格列酮和罗格列酮的人体药动学差异评价

我院2011－2012年164例次地高辛血药监测浓度回顾性分析

基因组学个体化给药对心脏瓣膜术后华法林初始抗凝疗效的影响

HPLC法测定人血浆中拉莫三嗪的浓度及其影响因素研究

个体化给药研究的文献分析